Drug intelligence / Profile preview

fentanyl + hydromorphone

Development stage: Phase 3
Lead developer: Johnson & Johnson
Modality: Small Molecules
Administration: Transdermal, Buccal, Sublingual, Intranasal, Intravenous, Intramuscular, Subcutaneous, Oral

Overview

Fentanyl and hydromorphone are both potent opioid analgesics used for pain management. Fentanyl is a synthetic opioid approximately 50-100 times more potent than morphine, while hydromorphone is a semi-synthetic opioid approximately 2-8 times more potent than morphine. Both medications bind to opioid receptors in the central nervous system to produce analgesia, with primary activity at mu-opioid receptors. They are Schedule II controlled substances with high potential for abuse and addiction.

Targets

DOR (Opioid Receptor Delta 1)KOR (Kappa opioid receptor)MOR (Mu opioid receptor)

Beyond the preview

Go deeper on fentanyl + hydromorphone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fentanyl + hydromorphone.